Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Pacira first quarter total revenues increase to $7.8 million

Pacira Pharmaceuticals, Inc. today announced consolidated financial results for the quarter ended March 31, 2012 and reviewed recent accomplishments, including the commercial launch in the United States of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain and the successful completion of an equity financing.

9 May 2012

Combination of Pressure Right device and antiemetics effective in reducing PONV

Pressure Point Inc. stated in a recent press release that in a peer reviewed research article appearing in the Anesthesia & Analgesia Journal last month entitled: Use of Disposable Acupressure Device, its Pressure Right acustimulation disposable (adhesive) wrist device confirmed a positive advantage when used as part of a multimodal antiemetic regimen. The clinical effects of the Pressure Right acupressure technique in a sham-controlled study comparison demonstrated a definite impact in reducing PONV.

9 May 2012

New analysis on why some soldiers never seek PTSD care

U.S. Army researcher Maj. Gary H. Wynn, M.D., shared new analysis on why some Soldiers suffering from combat-related post-traumatic stress disorder (PTSD) never seek care or drop out of treatment early during a presentation today at the American Psychiatric Association's annual meeting. His presentation, "Epidemiology of Combat-Related PTSD in U.S. Service Members: Lessons Learned," also described the approaches the Army is using to address this issue and improve overall patient outcomes.

8 May 2012

Oral zinc treatments may shorten duration of common cold symptoms in adults

Oral zinc treatments may shorten the duration of symptoms of the common cold in adults, although adverse effects are common, according to a study published in CMAJ.

8 May 2012

Everett Labs announces availability of Pregnitude for women with fertility problems

A new non-prescription Reproductive Support Dietary Supplement, Pregnitude, which contains myo-inositol (2 g), plus folic acid (200 mcg), is now available for women who are having difficulty conceiving, Everett Laboratories announced today. In clinical studies, Pregnitude has been shown to help support ovulation function and menstrual cycle regularity as well as support the quality of a woman's eggs.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Health Canada announces labelling update for Cipralex

Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).

7 May 2012

Low weight gain reported among women with nausea and vomiting of pregnancy

In one of the largest studies of its kind, clinicians and researchers with Carolinas HealthCare System found that nearly 25% of women with nausea and vomiting of pregnancy (NVP) reported weight gain below recommended levels for their pre-pregnancy body mass index (PPBMI).

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Teva announces new data from women's health franchise

Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in San Diego, California, May 5-9, 2012.

5 May 2012

CSL Behring commences C1-INH phase I/II study in hereditary angioedema

CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema.

4 May 2012

New pressure-technology device effective in reducing incidence of PONV

In a peer-reviewed published study, a new medically engineered pressure-technology disposable adhesive device (Pressure Right-) developed by Pressure Point Inc. has clinically proven to enhance the efficacy of a popular prophylactic antiemetic drug combination in reducing the incidence of postoperative nausea and vomiting (PONV) among high-risk patients after major laparoscopic surgery procedures.

3 May 2012

Dixie announces new hemp-based Cannabidiol products without THC

Dixie Elixirs and Edibles, Colorado's premier Tetrahydrocannabinol or THC-infused products company, today announced a new line of products which will break entirely new ground for the company in the category of non-THC-infused product development.

2 May 2012

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010.

2 May 2012

Antibiotic effective for plague gets FDA nod

Federal regulators – The Food and Drugs Administration (FDA), have approved use of an antibiotic to treat plague, an extremely rare, sometimes-fatal bacterial infection.

30 Apr 2012

Amoxicillin-clavulanate may improve small bowel function in children experiencing motility disturbances

The common antibiotic, amoxicillin-clavulanate, may improve small bowel function in children experiencing motility disturbances, according to a study appearing in the June print edition of the Journal of Pediatric Gastroenterology and Nutrition from Nationwide Children's Hospital.

30 Apr 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

BTG launches Voraxaze for treatment of toxic plasma methotrexate

BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

30 Apr 2012